Standing Order
All companies

Biotech

Recursion Pharmaceuticals, Inc.

RXRXNASDAQpure-play
Market cap$1.5B
Conviction3/ 5
HQSalt Lake City, Utah, USA
View full dashboard

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Price · 1Y

$2.45

-43.9%

Thesis

Recursion Pharmaceuticals runs an industrialized, automated biology platform that generates large datasets to train machine-learning models for drug discovery. Its scale and pharma partnerships aim to convert data advantages into a clinical pipeline.

Catalysts

  • Clinical-stage program readouts
  • Partnership milestone and option payments
  • Demonstrating platform-driven pipeline productivity

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 20
    OtherClinicalTrials.gov

    ClinicalTrials.gov update for NCT05985655 (GTAEXS617, Phase 1/2, advanced solid tumors): status changed to ACTIVE_NOT_RECRUITING; sponsored by Exscientia AI Ltd

  • Nov 2
    Financial resultsSEC

    8-K filing disclosing Q3 financial results (item 2.02) and leadership changes (item 5.02).

  • Oct 15
    Securities offeringSEC

    Recursion Pharmaceuticals filed Form 424B5 prospectus supplement.

  • Oct 15
    OtherSEC

    8-K filing covering items 1.01, 2.02, 7.01, 8.01, 9.01

  • Oct 15
    Securities offeringSEC

    Filed 424B5 prospectus supplement.

  • Sep 21
    DealSEC

    8-K item 1.01: entered into material definitive agreement.

  • Aug 13
    Trial initiationClinicalTrials.gov

    Exscientia (Recursion subsidiary) initiates Phase 1 dose-finding trial of EXS73565 in relapsed/refractory B-cell malignancies (NCT06980116, recruiting).

  • Aug 13
    Trial initiationClinicalTrials.gov

    Recursion subsidiary Exscientia updates NCT05985655 Phase 1/2 trial of GTAEXS617 in advanced solid tumors to recruiting status.

Not financial advice — research and opinion only. Disclosures